2024 Research Grant RFA – Shannon O’Boyle Memorial Grant – Neuropsychiatric Illness
The PMSF Board of Directors has established an annual research grant of $100,000 in honor of Shannon O’Boyle and to acknowledge…
US Updated consensus guidelines on the management of Phelan–McDermid syndrome
The objective of these updated clinical management guidelines was to: (1) reflect the latest in knowledge in PMS and (2) provide…
Catatonia: A Common Cause of Late Regression in Autism
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by social communication deficits and restricted interests and behaviors which begin very early in life. In about a quarter of cases, the symptoms emerge about 18–24 months after a period of normal development, a phenomenon commonly described as early regression. However, marked functional decline can also occur in persons with autism after a relatively stable childhood.
PMSF Neuropsychiatric Consultation Group – Case Presentation Form
Clinicians treating PMS individuals experiencing a neuropsychiatric event can use this form to reach out to the Neuropsychiatric Consultation Group. The…
Medical Advisory – Catatonia and Neuroleptic Malignant syndrome (NMS)
PMS is a rare genetic disorder which usually involves changes in a critical gene (SHANK3) on the longarm of chromosome 22.…
2023 PMSF and Developmental Synaptopathies Consortium – Neuropsychiatric Illness and Regression Fellowship
Data has emerged that a subset of individuals with Phelan-McDermid syndrome (PMS) experience devastating psychiatric symptoms, such as regression, bipolar disorder, and catatonia.
Neuropsychiatric Pharmacological Recommendations; 2022
These PMS Pharmacological Recommendations were developed by the PMS_Neuropsychiatric Consultation Group (PMS_NCG). These algorithms describe treatment suggestions for PMS individuals who have PMS who also carry a diagnosis of ADHD, Sleep Disturbance, Irritability and Aggression, Mood Cycling, and/or Catatonia.